Corporate Sites
https://www.bms.com/
https://www.celgene.com/
Healthcare Providers Site
Patients and Caregivers Site
Contact in CT:
Rich Boyle
Richard.Boyle@bms.com
Important News and Information
06/26/2025 U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
04/11/2025 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
04/08/20025 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer
COVID-19 Our Response and Path Forward - 05/13/2020
c/o Dawn Holcombe
dawnho@aol.com
33 Woodmar Circle South Windsor, CT 06074 (860) 305-4510
Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds